Beyond Plaques and Tau: Mapping the Networks of the Alzheimer’s Brain
August 17, 2026
Welcome to Greg Rowland’s Alzheimer’s Research Report.
Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.
Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:
Monthly Subscription: $10 per month
Annual Subscription: $100 per year (Save $20 annually)
Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)
I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Please consider subscribing so this publication is sustainable. Thank you!
SUMMARY
New PET network analysis from Indiana University suggests PharmatrophiX’s LM11A-31 may help preserve critical brain communication lines. Early clinical tests suggest that the oral drug, LM11A-31, may help preserve and reorganize the brain networks that support cognitive function in Alzheimer’s disease.
Subscribe and read the full report.
